Maria Reig, Jordi Rimola, Ferran Torres, Anna Darnell, Carlos Rodriguez‐Lope, Alejandro Forner, Neus LLarch, José Ríos, Carmen Ayuso, Jordi Bruix – 20 June 2013 – Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. Thus, time to tumor progression (TTP) is used to capture benefits of novel molecular agents, but proof of its surrogacy with survival is lacking.

Pablo Quintero, Marco Arrese – 20 June 2013

Taizo Hibi, Seigo Nishida, David M. Levi, Daisuke Sugiyama, Kyota Fukazawa, Akin Tekin, Ji Fan, Gennaro Selvaggi, Phillip Ruiz, Andreas G. Tzakis – 19 June 2013 – Aortohepatic conduits provide a vital alternative for graft arterialization during liver transplantation. Conflicting results exist with respect to the rates of comorbidities, and long‐term survival data on primary grafts are lacking.

Jeff Halldorson, John Paul Roberts – 19 June 2013 – After the foundation of the National Transplant Organization, Spanish rates of deceased donor donation rapidly outpaced US growth over the decade from 1989 to 1999. An analysis of the following decade, 1999‐2009, demonstrated a markedly flattened growth curve for Spanish deceased donor organ procurement, which increased only 2.4% from 33.6 to 34.4 donors per million population (pmp). In comparison, over the same decade in the United States, the rate of deceased donation increased from 20.9 to 26.3 donors pmp (25.8%).

Michael L. Volk, Meghan Roney, Robert M. Merion – 19 June 2013 – The decision to accept or decline a liver allograft for a patient on the transplant waiting list is complex. We hypothesized that surgeons are not accurate at predicting donor‐specific risks.

Rocío García Garza, Pablo Sarobe, Juana Merino, Juan J. Lasarte, Delia D'Avola, Virginia Belsue, José A. Delgado, Leyre Silva, Mercedes Iñarrairaegui, Bruno Sangro, Jesus J. Sola, Fernando Pardo, Jorge Quiroga, J. Ignacio Herrero – 19 June 2013 – Recipients of liver transplantation (LT) may develop immunological tolerance. Factors predictive of tolerance are not clearly understood.

Sumeet K. Asrani, W. Ray Kim, Erick B. Edwards, Joseph J. Larson, Gabriel Thabut, Walter K. Kremers, Terry M. Therneau, Julie Heimbach – 19 June 2013 – The hospital at which liver transplantation (LT) is performed has a substantial impact on post‐LT outcomes. Center‐specific outcome data are closely monitored not only by the centers themselves but also by patients and government regulatory agencies.

Amol S. Rangnekar, Caitlyn Ellerbe, Valerie Durkalski, Brendan McGuire, William M. Lee, Robert J. Fontana – 18 June 2013 – Functional outcomes for long‐term survivors of acute liver failure (ALF) are not well characterized. The aim of this prospective study was to determine health‐related quality of life in long‐term adult ALF survivors. Acute Liver Failure Study Group registry participants completed the Centers for Disease Control and Prevention Health‐Related Quality of Life 14 and Short Form 36 (SF‐36) questionnaires at 1‐ and/or 2‐year follow‐up study visits.

Jacqueline G. O'Leary, Hugo Kaneku, Linda W. Jennings, Nubia Bañuelos, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 18 June 2013 – Preformed donor‐specific human leukocyte antigen antibodies (DSAs) are considered a contraindication to the transplantation of most solid organs other than the liver. Conflicting data currently exist on the importance of preformed DSAs in rejection and patient survival after liver transplantation (LT).

Hassan Bholah, John Bate, Kathryn Rothwell, Mark Aldersley – 15 June 2013